Fiera Capital Corp Boosts Stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

Fiera Capital Corp raised its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 3.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 805,150 shares of the company’s stock after purchasing an additional 25,186 shares during the quarter. Fiera Capital Corp owned 1.61% of Immunocore worth $23,889,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. purchased a new stake in Immunocore in the fourth quarter valued at $25,000. Oppenheimer Asset Management Inc. purchased a new stake in Immunocore in the first quarter valued at $225,000. NEOS Investment Management LLC raised its position in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after purchasing an additional 1,102 shares during the period. Tema Etfs LLC purchased a new stake in Immunocore in the fourth quarter valued at $330,000. Finally, Virtus ETF Advisers LLC raised its position in Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after purchasing an additional 3,238 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Wall Street Analyst Weigh In

IMCR has been the topic of several research analyst reports. Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Deutsche Bank Aktiengesellschaft initiated coverage on Immunocore in a report on Tuesday, May 27th. They issued a “buy” rating and a $65.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Monday, June 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a report on Thursday, April 10th. Finally, Mizuho cut their price objective on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $58.89.

Immunocore Trading Down 0.1%

IMCR opened at $33.91 on Wednesday. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $40.52. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -78.86 and a beta of 0.77. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.36 and a quick ratio of 6.31. The business has a fifty day moving average price of $34.15 and a 200 day moving average price of $31.07.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. Immunocore had a negative return on equity of 5.86% and a negative net margin of 6.48%. The firm had revenue of $125.13 million during the quarter, compared to analysts’ expectations of $108.82 million. During the same period in the previous year, the firm posted ($0.49) EPS. Immunocore’s revenue for the quarter was up 33.6% on a year-over-year basis. Sell-side analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.